Kaleo Inc. said midday Thursday that its Auvi-Q allergic reaction treatment, a competitor to Mylan’s EpiPen, will be available starting Feb. 14 for $360. The company said the product would be available to many patients with commercial insurance, including high-deductible health plans, for no out-of-pocket cost, and that it would have a $360 cash price for those without insurance. Forbes reports that the product’s list price will be $4,500, several times higher than the cost of Mylan’s EpiPen, due to a complicated scheme through which Kaleo pays patients’ out-of-pocket costs directly to insurers. Mylan’s authorized generic EpiPen product became available in late December for around $300. The Auvi-Q was voluntarily recalled in 2015 over concerns about incorrect dose delivery, which the company told MarketWatch in October it has fixed. Mylan shares tumbled 26.3% over the last 12 months, compared with a 20.6% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News